An interventional study of N15-thymidine in Tetralogy of Fallot With Pulmonary Stenosis and Heart Failure, sponsored by Weill Medical College of Cornell University. Recruiting at 4 sites in United States. Open to participants aged 30 Days to 1 Year. Per ClinicalTrials.gov, last updated 2026-06-15.
Sponsored by Weill Medical College of Cornell University · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Heart Failure by Weill Medical College of Cornell University — 5 open to participants now, 5 under way, none of them phase 3. Heart Failure · Weill Medical College of Cornell University.
Among the 13 studies in Heart Failure by Weill Medical College of Cornell University, this one is the 7th largest by planned enrollment of the 12 interventional ones that give a count, is one of 4 that started in 2026, is one of 6 with no phase, and was the 10th registered.
6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.
Browse Heart Failure studies →5 of the 13 studies in Heart Failure by Weill Medical College of Cornell University are open now, in 1 country. Recruiting first, the newest first:
Weill Medical College of Cornell University · Sites in United States
Ages 18+ · Healthy volunteers
Weill Medical College of Cornell University · Sites in United States
Ages 65+
Weill Medical College of Cornell University · Sites in United States
Ages 65+
Weill Medical College of Cornell University · Sites in United States
Ages 60+
By country, each count listing its studies:
Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.
This study: 30 Days to 1 Year · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2020; this study’s year is marked. 4 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 76 across 4,053 interventional studies indexed under Heart Failure.
Median enrollment 40 across the 12 interventional studies, 33,100 across the 1 observational. Of the 8 that completed or were terminated, 5 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
Weill Medical College of Cornell University is the lead sponsor of 893 studies on the registry; 165 are open to participants now.
Of its 124 completed or terminated interventional studies of FDA-regulated products, 95 (77%) have results posted.
4 of the studies in Heart Failure by Weill Medical College of Cornell University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05585125Weill Medical College of Cornell UniversityA Preliminary Study for INFORMED | 2027-02 |
| NCT07252310Weill Medical College of Cornell UniversityPilot Study of StudyU for N-of-1 Trials in HFrEF Patients (N-of-1 App) | 2027-02 |
| NCT06587165Weill Medical College of Cornell UniversityQuantifying New Heart Muscle Cells | 2027-03-01 |
| NCT06118983Weill Medical College of Cornell UniversityImproving TRansitions ANd OutcomeS for Heart FailurE Patients in Home Health CaRe (I-TRANSFER-HF) | 2027-07-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 13 studies in Heart Failure by Weill Medical College of Cornell University, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Regenerative therapies could provide new ways of treating heart failure. Unlike many organs in the human body, such as the skin and the GI tract, the ability to regenerate heart muscle decreases after birth, but the precise timing of this decrease and how this decrease is altered in heart disease are uncertain. The investigators will use an innovative approach to quantify cellular heart regeneration in pediatric patients, an appropriate population for determining this decline as well as the potential for reactivating heart muscle regeneration.
The study has now been registered on ClinicalTrials.gov, despite its initiation on July 23, 2015, as registration was not mandated at the original study site, the University of Pittsburgh Medical Center. However, following the transfer of the study to Weill Cornell Medicine, adherence to institutional requirements necessitated its registration on ClinicalTrials.gov.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Study participants will receive thymidine preparations for pre-defined blocks of time prior to the scheduled routine resection of myocardium.
Other: N15-thymidine
50mg/kg (oral administration)
Percentage of labeled cardiomyocytes for each patient
The investigators will use, multi-isotope imaging mass spectrometry (MIMS) to quantify the generation of new cardiomyocytes by examining myocardial samples that are routinely resected and discarded during cardiac surgery. Investigators will then calculate the percentage of labeled, i.e. newly generated, cardiomyocytes, for each patient. The data from the analysis of myocardial samples will be the test results. Investigators will first compare these results with technical controls.
Time frame: 6 months
Plan to share: No
No publications or documents are linked to this record.
Started May 2026 (actual). Primary completion is estimated for Mar 2027, 9 months after the start.
Of 1,119 non-industry interventional studies with no phase under Heart Failure, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 50. This study's planned 9 months is below that.
Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Weill Medical College of Cornell University →